Catherine Ward
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Catherine Ward has a total of 45 co-authors. Here are the top co-authors by number of shared publications:
- Marc K. Hellerstein
Department of Nutritional Sciences & Toxicology, University of California at Berkeley, Berkeley, California, USA
13 shared publications - Andreas Stahl
Department of Nutrition and Toxicology, University of California Berkeley, Berkeley, USA
11 shared publications - Angela Misic
Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, USA
11 shared publications - Daniel K. Nomura
University of California, Berkeley
11 shared publications - Diego Francesco Calvisi
Institute of Pathology, University of Regensburg, Regensburg, Germany
11 shared publications - Diyala Shihadih
Department of Biology, Center for Teaching and Learning, University of New Mexico
11 shared publications
Latest Publications
- 26 August 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (11) , 1417-1425
Urinary Response to Consuming Plant-Based Meat Alternatives in Persons with Normal Kidney Function
Key Points: Eating plant-based meat versus eating animal meat is associated with lower urinary excretion of sulfate, ammonium, phosphorus, and urea nitrogen. Consuming plant-based meat compared with consuming animal meat is associated with higher urine pH and higher urinary excretion of citrate. Study findings suggest potential benefits of plant-based meat for patients with kidney disease. Background: Consuming excess animal meat may exacerbate kidney disorders, such as urinary stone disease and CKD. Plant-based meat alternatives imitate animal meat and replace animal with vegetable protein, but it is unclear whether eating plant-meat confers similar health benefits as eating whole vegetables. We hypothesized that eating plant-meat when compared with animal meat decreases dietary acid load but increases dietary phosphorus and nitrogen. Methods: The Study With Appetizing Plantfood—Meat Eating Alternatives Trial was a randomized 8-week, crossover trial (NCT03718988) of participants consuming ≥2 servings/d of either plant-meat or animal meat for each 8-week phase. We measured urine sulfate, ammonium, pH, phosphorus, urea nitrogen (UUN), citrate, and creatinine concentrations and serum creatinine and bicarbonate concentrations from stored participant samples from each phase. Results: At a single site, we enrolled 36 generally healthy participants (mean±SD age 50.2±13.8 years, 67% women, and 69% White). Eating the plant-meat diet versus eating the animal meat diet was associated with lower mean concentration of urine sulfate (−6.7 mEq/L; 95% confidence interval [CI], −11.0 to −2.4), urine ammonium (−4.2 mmol/L; 95% CI, −8.2 to −0.1), urine phosphorus (−9.0 mg/dl; 95% CI, −17.5 to −0.5), and UUN (−124.8 mg/dl; 95% CI, −226.9 to −22.6). Eating plant-meat compared with eating animal meat was associated with higher mean urine pH (+0.3 units; 95% CI, 0.2 to 0.5) and mean urine citrate/creatinine ratio (+111.65; 95% CI, 52.69 to 170.60). After participants consumed a plant-meat diet compared with when they consumed an animal meat diet, mean serum creatinine concentration was lower (−0.07 mg/dl, 95% CI, −0.10 to −0.04), whereas mean serum bicarbonate concentration was not different. Conclusions: Eating plant-based meat products, compared with eating animal meat, was associated with lower urinary excretion of sulfate, ammonium, phosphorus, and UUN and higher urinary excretion of citrate. Our findings provide rationale for examining whether plant-based meat will benefit patients with kidney disease. Clinical Trial registry name and registration number: NCT03718988.
- 26 August 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 19 (11) , 1417-1425
Urinary Response to Consuming Plant-Based Meat Alternatives in Persons with Normal Kidney Function
Key Points: Eating plant-based meat versus eating animal meat is associated with lower urinary excretion of sulfate, ammonium, phosphorus, and urea nitrogen. Consuming plant-based meat compared with consuming animal meat is associated with higher urine pH and higher urinary excretion of citrate. Study findings suggest potential benefits of plant-based meat for patients with kidney disease. Background: Consuming excess animal meat may exacerbate kidney disorders, such as urinary stone disease and CKD. Plant-based meat alternatives imitate animal meat and replace animal with vegetable protein, but it is unclear whether eating plant-meat confers similar health benefits as eating whole vegetables. We hypothesized that eating plant-meat when compared with animal meat decreases dietary acid load but increases dietary phosphorus and nitrogen. Methods: The Study With Appetizing Plantfood—Meat Eating Alternatives Trial was a randomized 8-week, crossover trial (NCT03718988) of participants consuming ≥2 servings/d of either plant-meat or animal meat for each 8-week phase. We measured urine sulfate, ammonium, pH, phosphorus, urea nitrogen (UUN), citrate, and creatinine concentrations and serum creatinine and bicarbonate concentrations from stored participant samples from each phase. Results: At a single site, we enrolled 36 generally healthy participants (mean±SD age 50.2±13.8 years, 67% women, and 69% White). Eating the plant-meat diet versus eating the animal meat diet was associated with lower mean concentration of urine sulfate (−6.7 mEq/L; 95% confidence interval [CI], −11.0 to −2.4), urine ammonium (−4.2 mmol/L; 95% CI, −8.2 to −0.1), urine phosphorus (−9.0 mg/dl; 95% CI, −17.5 to −0.5), and UUN (−124.8 mg/dl; 95% CI, −226.9 to −22.6). Eating plant-meat compared with eating animal meat was associated with higher mean urine pH (+0.3 units; 95% CI, 0.2 to 0.5) and mean urine citrate/creatinine ratio (+111.65; 95% CI, 52.69 to 170.60). After participants consumed a plant-meat diet compared with when they consumed an animal meat diet, mean serum creatinine concentration was lower (−0.07 mg/dl, 95% CI, −0.10 to −0.04), whereas mean serum bicarbonate concentration was not different. Conclusions: Eating plant-based meat products, compared with eating animal meat, was associated with lower urinary excretion of sulfate, ammonium, phosphorus, and UUN and higher urinary excretion of citrate. Our findings provide rationale for examining whether plant-based meat will benefit patients with kidney disease. Clinical Trial registry name and registration number: NCT03718988.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Clinicopathological features of ICC patients
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Clinicopathological features of ICC patients
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Clinicopathological features of ICC patients
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Clinicopathological features of ICC patients
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
The comprehensive information about all detected lipids
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
The comprehensive information about all detected lipids
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Gene expression levels of FATP5 were measured using qPCR in 5 normal livers (NL), 33 ICC, and related surrounding livers (SL).
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Gene expression levels of FATP5 were measured using qPCR in 5 normal livers (NL), 33 ICC, and related surrounding livers (SL).
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Gene expression levels of Fatp5, and Fasn were measured using qPCR in AAV-shSCR and AAV-shFatp5 ICC tumors.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Gene expression levels of Fatp5, and Fasn were measured using qPCR in AAV-shSCR and AAV-shFatp5 ICC tumors.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Gene expression levels of Fatp5, and Fasn were measured using qPCR in AAV-shSCR and AAV-shFatp5 ICC tumors.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Gene expression levels of Fatp5, and Fasn were measured using qPCR in AAV-shSCR and AAV-shFatp5 ICC tumors.
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
The comprehensive information about all detected lipids
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
The comprehensive information about all detected lipids
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Gene expression levels of FATP5 were measured using qPCR in 5 normal livers (NL), 33 ICC, and related surrounding livers (SL).
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Gene expression levels of FATP5 were measured using qPCR in 5 normal livers (NL), 33 ICC, and related surrounding livers (SL).
- Open Access
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Data from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Altered lipid metabolism is a common hallmark of various cancers, including intrahepatic cholangiocarcinoma (ICC), a highly lethal carcinoma that lacks effective treatment options. To elucidate the lipid metabolism changes in ICC, we coupled the expression of the firefly luciferase gene (FFL) to AKT1 (AKT-FFL) via an IRES linker, and then hydrodynamically injected mice with AKT-FFL and Notch1 intracellular cytoplasmic domain (NICD) to establish a luciferase-positive ICC model. This model not only enabled us to monitor and quantify tumor growth by injecting the mice with luciferin, but also allowed us to assess the fatty acid uptake rate by injecting the mice with free fatty acid luciferin (FFA-Luc). The ICC model exhibited robust uptake of exogenous fatty acids compared with the HCC model induced by AKT-FFL/ neuroblastoma Ras (Ras). Lipidomics analysis showed a dramatically higher level of fatty acid in ICC, further supporting the increased fatty acids uptake. Mechanistic studies identified FATP5 as the predominant mediator of fatty acid uptake required for ICC growth using Fatp5 knockout mice and AAV-based shRNA silencing of Fatp5. Our study discovered a novel therapeutic target for the treatment of ICC and shed light on the contributions of lipid metabolism to ICC development.Implications:This study provides the first in vivo evidence that FATP5 is a potential therapeutic target for treating ICC.
- 4 June 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from FATP5 Is Indispensable for the Growth of Intrahepatic Cholangiocarcinoma
Altered lipid metabolism is a common hallmark of various cancers, including intrahepatic cholangiocarcinoma (ICC), a highly lethal carcinoma that lacks effective treatment options. To elucidate the lipid metabolism changes in ICC, we coupled the expression of the firefly luciferase gene (FFL) to AKT1 (AKT-FFL) via an IRES linker, and then hydrodynamically injected mice with AKT-FFL and Notch1 intracellular cytoplasmic domain (NICD) to establish a luciferase-positive ICC model. This model not only enabled us to monitor and quantify tumor growth by injecting the mice with luciferin, but also allowed us to assess the fatty acid uptake rate by injecting the mice with free fatty acid luciferin (FFA-Luc). The ICC model exhibited robust uptake of exogenous fatty acids compared with the HCC model induced by AKT-FFL/ neuroblastoma Ras (Ras). Lipidomics analysis showed a dramatically higher level of fatty acid in ICC, further supporting the increased fatty acids uptake. Mechanistic studies identified FATP5 as the predominant mediator of fatty acid uptake required for ICC growth using Fatp5 knockout mice and AAV-based shRNA silencing of Fatp5. Our study discovered a novel therapeutic target for the treatment of ICC and shed light on the contributions of lipid metabolism to ICC development.Implications:This study provides the first in vivo evidence that FATP5 is a potential therapeutic target for treating ICC.